Natera, Inc. · NASDAQ:NTRA
Natera — 39th Annual J.P. Morgan Healthcare Conference 2021
19 slides from Natera's conference presentation, Jan 12, 2021
Slide 1: Natera, Inc. Investor presentation
Natera, Inc. Investor presentation January 2021 JP Morgan Conference
Slide 2: Leader in cell-free DNA technology
Leader in cell-free DNA technology • >3 million 2013 2020 tests performed Panorama NIPT launch ONCOLOGY • Leader in published data across cell-free DNA applications WOMEN’S HEALTH • 250+ technology patents, ORGAN HEALTH >100 issued 2 Not for reproduction or further distribution.
Slide 3: We hit our goals in 2020
We hit our goals in 2020 2020 Goals Achieved Well Positioned for 2021 •1 Extend leadership position • ~1 million tests processed, momentum in reproductive health from average risk coverage and SMART study •2 Change patient care • Pre-pandemic Prospera volume growth for transplant recipients targets
Slide 4: Our formula for success
Our formula for success Bleeding-edge Extreme focus on technology + user experience constant innovation + support services #1 in clinical Broad + talented data + expert commercial teams clinical teams 4 Not for reproduction or further distribution.
Slide 5: Leadership position in reproductive health
Leadership position in reproductive health Test volumes – reproductive health products ~ 1MM 794K 669K 515K 447K 317K 218K 88K 2013 2014 2015 2016 2017 2018 2019 2020 5 Not for reproduction or further distribution.
Slide 6: Average risk NIPT is just getting started
Average risk NIPT is just getting started ACOG/SMFM support 4.2 million births in U.S. ~3.4M ~0.8M High Risk Market Average Risk Market Current Market Penetration Source: internal company estimates 6 Not for reproduction or further distribution.
Slide 7: SMART trial analysis complete, reading out in early '21
SMART trial analysis complete, reading out in early ‘21 Study design Future Impact • 20,000 patient prospective clinical trial • Further differentiates Natera’s SNP-based approach; others use shotgun sequencing • Two major publications expected in 2021: • Market share: best in class performance, – L
Slide 8: Transplant: Pathway to significant revenue opportunity
Transplant: Pathway to significant revenue opportunity Total tests Revenue sensitivity • $2B market ($ in millions) $98 $84 • < 10% $70 penetrated greenfield $56 $42 Total 3% 4% 5% 6% 7% < 10% Market penetration Source: internal company estimates 8 Not for reproduction or further distribution.
Slide 9: Background cf-DNA validation further differentiates Prospera
Background cf-DNA validation further differentiates Prospera Background cf-DNA COVID-19 studies • Launched at ATC, May 2020 • Upcoming Natera publications studying background cf-DNA in transplant patients • New real-world data presented at ASN with COVID-19 2 pubs soon to be showing clinical utility
Slide 10: Oncology MRD market opportunity
Oncology MRD market opportunity ctDNA / Liquid biopsy Early Monitoring Therapy detection $15B selection Source: internal company estimates 10 Not for reproduction or further distribution.
Slide 11: How Signatera works – personalized and tumor-informed MRD
How Signatera works – personalized and tumor-informed MRD Sequencing of Custom design and manufacture Use personalized assay to tumor tissue, to identify of personalized mPCR assay for test patient’s blood for unique signature of each patient, targeting the top 16 presence of circulating tumor mutat
Slide 12: Signatera validated across multiple tumor types
Signatera validated across multiple tumor types JAMA Oncology Clinical Cancer Research Nature Journal of Clinical Oncology Colon1 Breast2 Lung3 Bladder4 1.00 1.00 1.00 1.00 ctDNA negative ctDNA negative ctDNA negative ctDNA negative % Relapse-free survival % Relapse-free survival % Relapse-free surv
Slide 13: Acceleration in Pharma business, ~$120M signed to date
Acceleration in Pharma business, ~$120M signed to date Value of new signed contracts • Average deal size getting larger, including multiple phase 3 trials with >$65M patient volume and development fees • Two key benefits for pharma: 1. Study enrichment: $46M treating only MRD-positive patients, for
Slide 14: Phase III IMvigor study proved Signatera is predictive of treatment benefit
Phase 3 IMvigor study proved that Signatera is predictive of treatment benefit in the adjuvant setting ● Background: Overall survival in MIBC patients treated – GNE-sponsored, PhIII randomized controlled with adjuvant atezolizumab vs. observation1 trial of atezo vs. obs in adjuvant bladder cancer. P
Slide 15: Medicare final LCD and launch in colorectal cancer
Medicare final LCD and launch in colorectal cancer ● Est. opportunity ~1 million tests annually ● Over 85% of relapses caught too late for curative surgery1-2 Adjuvant MRD Program Surveillance Program Use Signatera after surgery to evaluate the Use Signatera alongside CEA to detect need for adjuvant
Slide 16: Medicare draft LCD in IO response monitoring
Medicare draft LCD in IO response monitoring Regimen A Regimen B ● > 200,000 patients treated CT #1 CT #2 CT #3 with immunotherapy (IO) annually, most do not respond1 ● Pseudo-progression delays identification of non-responders, SignateraTM Signatera combined with imaging shown to identify 100% of n
Slide 17: Extending our data leadership in MRD
Extending our data leadership in MRD 7 clinical studies published 50+ studies in pipeline 1. CRC – Reinert et al (JAMA Oncology) • Breast • Colorectal 2. IO pan-cancer – Bratman et al (Nature • Melanoma • Lung Cancer) 2 pubs soon to be • Renalpublished • Prostate 3. Lung – Abbosh et al (Nature) • Pa
Slide 18: Oncology MRD market opportunity
Oncology MRD market opportunity Tests per year 600K ~2.4M 800K 1M Stage II-III IO response New published & Total Total CRC monitoring presented indications Source: internal estimates 18 Not for reproduction or further distribution.
Slide 19: ©2021 Natera, Inc. All Rights Reserved. Not for reproduction or further distribution.
©2021 Natera, Inc. All Rights Reserved. Not for reproduction or further distribution.
Natera — 39th Annual J.P. Morgan Healthcare Conference 2021 on 6ix